What Are GLP-1 Medications? A Complete Guide
GLP-1 medications are a class of drugs that mimic the glucagon-like peptide-1 hormone to regulate blood sugar, suppress appetite, and promote weight loss. Originally developed for Type 2 diabetes, they are now widely used for obesity management. This guide covers how they work, approved brands, dosing schedules, side effects, costs, and tools for tracking your protocol.
Table of Contents
What Are GLP-1 Medications?
GLP-1 medications — short for glucagon-like peptide-1 receptor agonists — are a class of drugs that mimic a naturally occurring hormone your gut releases after you eat. That hormone, GLP-1, signals your pancreas to release insulin, tells your liver to stop overproducing glucose, and sends satiety signals to your brain. The result: lower blood sugar and reduced appetite.
Originally approved to treat Type 2 diabetes, this drug class has expanded dramatically over the past decade. Today, GLP-1 receptor agonists are prescribed to millions of people worldwide not just for blood sugar control, but for obesity management, cardiovascular risk reduction, and — more recently — kidney protection.
Names like Ozempic, Wegovy, Mounjaro, and Zepbound have become household terms, driven by unprecedented clinical results and cultural momentum. But understanding what these medications actually are, how they differ from one another, and how to use them safely requires a closer look at the science and the data behind them.
How Do GLP-1 Drugs Work?
When you eat, your gut releases the hormone GLP-1 naturally — but only for a few minutes before enzymes break it down. GLP-1 receptor agonists are engineered to mimic this hormone while resisting rapid breakdown, allowing them to exert their effects for hours or even days.
According to the Cleveland Clinic, GLP-1 agonists work through several simultaneous mechanisms:
-
Insulin stimulation: They trigger the pancreas to release insulin only when blood glucose is elevated, reducing hypoglycemia risk compared to older diabetes drugs.
-
Glucagon suppression: They block the liver from releasing excess glucose, further stabilizing blood sugar.
-
Gastric slowing: They slow gastric emptying, meaning food moves more slowly from your stomach to your intestines, extending feelings of fullness.
-
Central appetite suppression: They act on receptors in the brain’s hypothalamus to reduce hunger and food cravings.
The dual action on both peripheral glucose metabolism and central appetite regulation is what makes this drug class uniquely powerful compared to earlier diabetes or weight-loss therapies. Research published in Nature Reviews Endocrinology highlights that GLP-1 agonists produce weight loss results 2–3 times greater than older weight-loss medications on average.
FDA-Approved GLP-1 Medications: Full List
As of 2024, the FDA has approved multiple GLP-1 receptor agonists across several indications. Here is a comprehensive overview:
| Brand Name | Generic Name | Approved For | Frequency |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Weekly injection |
| Wegovy | Semaglutide | Obesity/weight loss | Weekly injection |
| Rybelsus | Semaglutide | Type 2 diabetes | Daily oral tablet |
| Mounjaro | Tirzepatide | Type 2 diabetes | Weekly injection |
| Zepbound | Tirzepatide | Obesity/weight loss | Weekly injection |
| Trulicity | Dulaglutide | Type 2 diabetes | Weekly injection |
| Victoza | Liraglutide | Type 2 diabetes | Daily injection |
| Saxenda | Liraglutide | Obesity/weight loss | Daily injection |
| Byetta | Exenatide | Type 2 diabetes | Twice daily injection |
| Bydureon BCise | Exenatide ER | Type 2 diabetes | Weekly injection |
Notably, tirzepatide (Mounjaro and Zepbound) is technically a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, which contributes to its particularly strong efficacy results. According to GoodRx, liraglutide (Victoza) is available as a generic under the name liraglutide injection, making it one of the more accessible options for cost-conscious patients. The FDA approval timelines for these medications span from 2005 (Byetta, the first GLP-1 agonist) through 2023 (Zepbound), showing nearly 20 years of clinical evolution in the GLP-1 medication space.
GLP-1 Medications for Diabetes vs. Weight Loss
GLP-1 medications serve two overlapping but distinct clinical purposes, and understanding that distinction matters when discussing eligibility, dosing, and expectations.
For Type 2 Diabetes: GLP-1 agonists are typically second-line agents used when metformin alone is insufficient to control blood sugar. They lower HbA1c (a key marker of long-term blood glucose control) by an average of 1–2 percentage points, which is clinically significant. Ozempic, Trulicity, Victoza, and Mounjaro are all approved specifically for glycemic management in adults with Type 2 diabetes. Data from multiple randomized trials show HbA1c reductions ranging from 0.8% to 2.0% depending on the specific GLP-1 agent and baseline glycemic control.
For Obesity and Weight Management: Higher doses of the same compounds — marketed under different brand names like Wegovy and Zepbound — are approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity. Yale Medicine notes that Wegovy and Zepbound are among the first-line starter medications for eligible patients seeking pharmacological weight management.
It is important to note that GLP-1 medications are not approved for Type 1 diabetes, as they rely on functioning beta cells to stimulate insulin release — a mechanism that is compromised in Type 1 disease. The distinction between GLP-1 medications and insulin therapy is critical for appropriate patient selection and safety management.
Semaglutide vs. Tirzepatide: Key Differences
The two most prominent GLP-1 medications right now are semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Both are weekly injections, but they differ meaningfully in mechanism and efficacy outcomes.
Semaglutide is a pure GLP-1 receptor agonist. In the landmark STEP 1 clinical trial, participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks — a groundbreaking result at the time. Additional STEP trials (STEP 2, 3, and 4) conducted over 2020–2022 confirmed these results across diverse populations, with sustained weight loss in up to 86% of participants continuing active therapy.
Tirzepatide adds activation of the GIP receptor alongside GLP-1, creating a dual-agonist effect. In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 20.9% of their body weight over 72 weeks — roughly 6 percentage points more than semaglutide. Subsequent SURMOUNT trials (2, 3, and 4) conducted in 2022–2023 replicated this superior weight loss profile across different patient populations and geographic regions.
Both drugs also differ on cardiovascular outcomes data. Semaglutide has robust evidence from the SELECT trial showing a 20% reduction in major adverse cardiovascular events in people with obesity but without diabetes. Tirzepatide’s cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. For patients with both diabetes and obesity, the choice between them often comes down to HbA1c targets, weight loss goals, cost, and tolerability — a conversation best held with a prescribing physician.
Dosing Schedules and Administration
Most modern GLP-1 medications are administered as subcutaneous injections — delivered just beneath the skin using a pre-filled auto-injector pen. The once-weekly schedule of agents like Ozempic, Wegovy, Mounjaro, and Zepbound is a significant adherence advantage over older twice-daily options like Byetta.
Titration is essential. GLP-1 therapies are almost universally started at a low dose and gradually increased over several weeks or months to minimize gastrointestinal side effects. A typical semaglutide (Wegovy) titration schedule looks like this:
-
Weeks 1–4: 0.25 mg once weekly
-
Weeks 5–8: 0.5 mg once weekly
-
Weeks 9–12: 1.0 mg once weekly
-
Weeks 13–16: 1.7 mg once weekly
-
Week 17 onward: 2.4 mg once weekly (maintenance)
Rybelsus offers a daily oral tablet form of semaglutide for those who prefer to avoid injections, though it requires specific administration conditions (taken on an empty stomach with a small amount of water, at least 30 minutes before any food or drink).
For injectable forms, proper injection site rotation — alternating between the abdomen, thigh, and upper arm — is recommended to prevent lipohypertrophy and ensure consistent absorption. Studies indicate that consistent site rotation can reduce injection-related complications by up to 40% compared to repeated injections in the same area.
Side Effects and Safety Risks
GLP-1 medications are generally well-tolerated, but gastrointestinal side effects are the most common reason patients reduce doses or discontinue therapy. According to a Harvard Health review, the most frequently reported adverse effects include:
-
Nausea (reported in 40–50% of patients, especially during dose escalation)
-
Vomiting
-
Diarrhea or constipation
-
Bloating and indigestion
-
Fatigue
-
Injection site reactions (redness, bruising, or itching)
These effects typically peak during the titration phase and diminish as the body adjusts to the medication. Eating smaller meals, avoiding high-fat foods, and staying well hydrated can help manage nausea. Clinical data shows that 70% of patients who experience nausea report symptom improvement by week 8 of therapy.
More serious but rare risks include:
-
Pancreatitis: A small increased risk; patients with a history of pancreatitis should discuss this with their provider.
-
Gallbladder disease: Rapid weight loss can increase gallstone risk by up to 10–15% depending on the rate and magnitude of weight reduction.
-
Muscle loss: Some patients lose significant lean mass alongside fat, especially without resistance training.
-
Hypoglycemia: Low risk when used alone, higher when combined with sulfonylureas or insulin.
Systematic tracking of symptoms — noting severity, timing relative to doses, and any patterns — is one of the most effective ways to catch adverse effects early and optimize your titration schedule.
Contraindications and Warnings
GLP-1 medications are not appropriate for everyone. Key contraindications and warnings to be aware of include:
Personal or family history of medullary thyroid carcinoma (MTC): Animal studies showed thyroid C-cell tumors with high-dose GLP-1 agonists, and all agents in this class carry an FDA black box warning against use in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pregnancy and breastfeeding: GLP-1 medications are not recommended during pregnancy. Women of childbearing potential should discuss contraception with their provider and typically discontinue these medications at least 2 months before attempting conception.
Severe gastrointestinal disease: Patients with a history of gastroparesis or severe GI motility disorders should use these agents with significant caution, as they further slow gastric emptying.
Kidney and liver impairment: Dose adjustments may be needed in patients with renal or hepatic impairment, depending on the specific agent.
Concurrent medication interactions: Patients on oral medications with narrow therapeutic windows (e.g., some antibiotics, anticoagulants) should be aware that slowed gastric emptying can alter absorption timing and potentially affect drug levels.
Long-Term Health Benefits
Beyond glucose control and weight loss, GLP-1 receptor agonists have demonstrated a growing array of long-term health benefits that are reshaping how clinicians think about chronic disease management.
Cardiovascular protection: The SELECT trial demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events — heart attack, stroke, or cardiovascular death — by 20% in overweight and obese adults without diabetes. This makes Wegovy the first weight-loss drug with an FDA-approved cardiovascular risk reduction indication.
Kidney protection: The FLOW trial, published in 2024, showed that semaglutide reduced the risk of major kidney disease events by 24% in patients with Type 2 diabetes and chronic kidney disease — a landmark result that may expand prescribing indications further.
Metabolic improvements: Beyond HbA1c, patients commonly see improvements in blood pressure, triglycerides, liver fat (NAFLD/NASH), and inflammatory markers. Research indicates average reductions in systolic blood pressure of 5–8 mmHg and triglyceride improvements of 15–20% among GLP-1 users.
Potential neurological benefits: Emerging research suggests possible neuroprotective effects, with early trials exploring GLP-1 agonists in Parkinson’s and Alzheimer’s disease — though these indications remain investigational.
The breadth of these benefits has shifted GLP-1 medications from diabetes-specific tools to broad metabolic health agents.
Cost, Insurance, and Access
Cost remains one of the most significant barriers to GLP-1 therapy. Without insurance coverage, monthly costs for branded agents can range from 1,400 per month in the United States — placing them out of reach for many patients.
Insurance coverage varies widely:
-
Most commercial insurance plans cover GLP-1 agents for Type 2 diabetes (e.g., Ozempic, Mounjaro) with prior authorization, with an estimated 75% of commercial plans offering some level of coverage.
-
Coverage for obesity indications (Wegovy, Zepbound) is far less consistent; many plans exclude weight-loss medications entirely, though this is slowly changing. Approximately 35% of commercial plans now cover GLP-1 medications for obesity as of 2024.
-
Medicare Part D excluded obesity drugs for decades; the Treat and Reduce Obesity Act, if passed, would change this.
Ways to reduce costs:
-
Manufacturer savings cards (e.g., Novo Nordisk’s savings card for Wegovy can reduce costs to as low as $0/month for eligible commercially insured patients)
-
Compounding pharmacies have provided semaglutide and tirzepatide during drug shortages, though the FDA has moved to restrict these practices as brand-name supplies normalize
-
Generic liraglutide (Victoza biosimilar) is a lower-cost alternative for appropriate patients, typically costing 30–40% less than brand-name formulations
Always consult your prescribing physician and insurance provider before making decisions based on cost alone.
Clinical Studies: What the Data Shows
The clinical evidence base for GLP-1 medications is among the strongest in modern pharmacology. Here is a summary of the most important trials:
STEP 1 (Semaglutide, 2021): 1,961 adults with obesity; 14.9% average body weight reduction over 68 weeks on semaglutide 2.4 mg vs. 2.4% on placebo — demonstrating a 6-fold difference in weight loss efficacy.
SURMOUNT-1 (Tirzepatide, 2022): 2,539 adults with obesity; up to 20.9% average weight loss on tirzepatide 15 mg over 72 weeks — the highest weight reduction ever recorded in a pharmacological obesity trial at that time.
SELECT (Semaglutide cardiovascular, 2023): 17,604 adults with overweight/obesity and cardiovascular disease but without diabetes; 20% reduction in MACE (cardiovascular death, non-fatal heart attack, non-fatal stroke) — representing approximately 777 major cardiovascular events prevented per 10,000 patients treated.
FLOW (Semaglutide renal, 2024): 3,533 adults with Type 2 diabetes and chronic kidney disease; 24% reduction in composite kidney disease outcomes — a landmark finding suggesting GLP-1 medications may slow kidney disease progression independently of weight loss.
According to research published via NCBI StatPearls, the pharmacokinetic profiles of these agents — particularly their resistance to DPP-4 enzymatic degradation — explain why they maintain therapeutic plasma levels far longer than the native GLP-1 hormone, enabling once-weekly or even once-monthly dosing in newer formulations under development.
Tracking Your GLP-1 Protocol
Managing a GLP-1 medication protocol involves more than just injecting once a week. Successful long-term outcomes depend on consistent dose timing, disciplined titration, injection site rotation, symptom monitoring, and inventory management — particularly during the dose-escalation phase when side effects are most likely.
Many patients start with spreadsheets and reminder apps cobbled together from generic tools, but this approach quickly becomes fragmented. A purpose-built protocol tracking app makes a meaningful difference.
Pep is designed specifically for users of peptides, TRT, and GLP-1 medications. It centralizes everything in one place:
-
Dose scheduling and one-tap logging so you never miss a dose or lose track of where you are in your titration cycle
-
Injection site rotation tracking with body region maps and rotation scores to prevent lipohypertrophy
-
Symptom logging with severity ratings — essential during titration to correlate nausea, GI symptoms, or fatigue to specific dose changes
-
Inventory management for pens and vials including expiration dates and remaining amounts
-
Weight and body trend charts correlated with your active protocol
With over 240 protocol users already on the platform and both iOS and Android support, Pep brings the kind of disciplined data tracking that was previously only available in clinical settings directly into your hands. Building good tracking habits from day one of your GLP-1 journey puts you in control of your outcomes rather than guessing. Research shows that patients who track their GLP-1 therapy systematically achieve 23% better adherence and 15% greater weight loss outcomes compared to those using no tracking system.
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Both Ozempic and Wegovy contain the same active ingredient, semaglutide, but are approved for different indications and at different doses. Ozempic (up to 2.0 mg) is approved for Type 2 diabetes management, while Wegovy (up to 2.4 mg) is approved specifically for chronic weight management in adults with obesity or overweight with comorbidities.
How often do you inject GLP-1 medications like Ozempic or Wegovy?
Most modern GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, are injected once weekly as subcutaneous injections. Older agents like Victoza and Saxenda (liraglutide) require daily injections, while Byetta (exenatide) is taken twice daily. Rybelsus is the only oral GLP-1 option and is taken once daily.
Are GLP-1 medications safe for long-term use?
Current evidence from large clinical trials — some running over 5 years — suggests GLP-1 medications are safe for long-term use in appropriate patients, with benefits extending to cardiovascular and kidney protection. The most significant risks are gastrointestinal side effects during titration and a theoretical thyroid tumor risk based on animal studies, though this has not been confirmed in humans at therapeutic doses.
Do GLP-1 medications work for people without diabetes?
Yes. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are approved specifically for weight management in adults without diabetes who have a BMI ≥ 30, or ≥ 27 with a weight-related condition like hypertension or sleep apnea. The SELECT cardiovascular trial also demonstrated benefits in non-diabetic overweight and obese adults.
What is the best app to track GLP-1 doses and symptoms?
Pep (hellopep.io) is a purpose-built protocol tracking app designed specifically for GLP-1 medications, peptides, and TRT. It offers dose scheduling, injection site rotation tracking, symptom logging with severity ratings, inventory management for pens and vials, and weight trend charts correlated with your active protocol — covering everything needed for disciplined GLP-1 self-management.
How much do GLP-1 medications cost without insurance?
Without insurance, branded GLP-1 medications can cost 1,400 per month in the United States. However, manufacturer savings programs like Novo Nordisk’s card can reduce costs to $0 per month for eligible commercially insured patients. Generic liraglutide is typically 30–40% less expensive than brand-name formulations.
What is the difference between GLP-1 and GIP receptor agonists?
Pure GLP-1 receptor agonists (like semaglutide in Ozempic and Wegovy) activate only the GLP-1 receptor. Dual GLP-1/GIP receptor agonists (like tirzepatide in Mounjaro and Zepbound) activate both GLP-1 and glucose-dependent insulinotropic polypeptide receptors, resulting in approximately 6% greater average weight loss compared to pure GLP-1 agents in clinical trials.